TC Biopharm (Holdings) Plc (TCBP) Research

Operating as a clinical-stage biopharmaceutical entity, TC Biopharm (Holdings) Plc is dedicated to pioneering immunotherapy solutions, leveraging its proprietary allogeneic gamma delta T cell platform. Its developmental portfolio includes OmnImmune, an unmodified cellular therapy aimed at acute myeloid leukemia, and ImmuniStim, another unmodified cellular therapy designed to combat COVID-19. The company was established in 2013 and is headquartered in Motherwell, United Kingdom.

Market snapshot

Symbol
TCBP
Price
$0.50
Day change
0.00%
Market cap
$193.8K
P/E ratio
-0.00x
52-week range
0.08-523.2
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Bellerophon Therapeutics, Inc. (BLPH)
  • Histogen Inc. (HSTO)
  • Immatics N.V. (IMTX)
  • Leafly Holdings, Inc. (LFLY)
  • LakeShore Biopharma Co., Ltd (LSB)
  • ProSomnus, Inc. (OSA)
  • Phio Pharmaceuticals Corp. (PHIO)
  • Seelos Therapeutics, Inc. (SEEL)

Recent insider activity

  • Randall Diana Elizabeth — P-Purchase (70000 shares) on 2022-11-30
  • Randall Mark Edward — P-Purchase (70000 shares) on 2022-11-30
  • Randall Mark Edward — P-Purchase (70000 shares) on 2022-11-30
  • Randall Mark Edward — P-Purchase (70000 shares) on 2022-11-30
  • Randall Kenneth Edward — P-Purchase (70000 shares) on 2022-11-30

Open TC Biopharm (Holdings) Plc (TCBP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.